Skip to main content

CASE REPORT article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1496342
This article is part of the Research Topic Checkpoint Immunotherapy: Reshaping the Landscape of Gastrointestinal Cancer Treatment View all 5 articles

Hepatoid adenocarcinoma of stomach with ideal response to neoadjuvant chemo-immunotherapy: a case report

Provisionally accepted
Linchuan Li Linchuan Li 1,2Dexu Zhang Dexu Zhang 3Jiankang Zhu Jiankang Zhu 1,2Guangyong Zhang Guangyong Zhang 1,2*
  • 1 Department of General Surgery, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Jinan, Shandong Province, China
  • 2 Department of General Surgery, Shandong Provincial Qianfoshan Hospital, The First Affiliated Hospital of Shandong First Medical University, Laboratory of Metabolism and Gastrointestinal Tumor, Jinan, Shandong Province, China
  • 3 Shandong Provincial Qianfoshan Hospital, Shandong University, Shandong, China

The final, formatted version of the article will be published soon.

    Hepatoid adenocarcinoma of stomach (HAS) is a rare subtype of gastric cancer characterized by histological features resembling hepatocellular carcinoma.Surgical intervention remains the preferred treatment modality for eligible patients. However, the efficacy of neoadjuvant therapy and alternative treatment regimens has been found to be suboptimal. Consequently, due to the high metastatic potential and unfavorable biological behavior of HAS, the prognosis for affected patients is exceedingly poor. We present a case involving a 64-yearold male diagnosed with advanced HAS, who demonstrated significant antitumor responses following a preoperative regimen of chemotherapy combined with immunotherapy, specifically utilizing oxaliplatin, S-1, and sintilimab. Over a two-month period of neoadjuvant therapy, the patient's serum α-fetoprotein level markedly decreased from 52,951.56 ng/mL to 241.04 ng/mL. Computed tomography scans revealed substantial tumor regression. Subsequent radical surgical intervention confirmed significant tumor shrinkage, with no evidence of lymph node metastasis upon pathological examination. This is the first report of chemotherapy combined with sintilimab in the treatment of gastric hepatoid adenocarcinoma, which may provide novel insights into the therapeutic strategy for HAS.

    Keywords: Hepatoid adenocarcinoma of stomach, Immunotherapy, chemotherapy, Programmed cell death-ligand 1, Laparoscopic gastrectomy, gastric cancer

    Received: 14 Sep 2024; Accepted: 18 Dec 2024.

    Copyright: © 2024 Li, Zhang, Zhu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Guangyong Zhang, Department of General Surgery, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Jinan, 250014, Shandong Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.